Bone histomorphometry of ovariectomized or orchiectomized rats fed a moderately magnesium-deficient fructose diet and treated with exogenous oestrogen or testosterone.
To investigate the effects of sex hormones on bone histomorphometry, and bone density (BMD), 10 week old ovariectomized (OVX), orchiectomized (ORX), and sham-operated (SHAM) rats fed a moderately magnesium-deficient fructose diet were studied. One third of the OVX and ORX rats were injected with beta-oestradiol-3-benzoate; another third, testosterone cypionate; and the remaining SHAM rats, vehicle only. After 14 weeks, a 24 h urine sample was collected for measurements of calcium, phosphorus and cyclic AMP (cAMP). Blood was collected for determination of calcium, phosphorus, and parathyroid hormone (PTH). Femurs and tibias were removed and weighed. Femurs were used to measure bone areas, mineral contents (BMC), and BMD. Tibias were used for bone histomorphometry (that is, trabecular numbers, thicknesses, % areas and separations). Oestrogen treatment increased serum and urine calcium significantly in both OVX and ORX rats, whereas testosterone decreased serum and urine calcium significantly. Oestrogen decreased urinary cAMP and PTH in both OVX and ORX rats, whereas testosterone treatment increased them significantly. Oestrogen treatment increased BMD, trabecular numbers, thicknesses, and % areas, and decreased bone separations in both OVX and ORX rats. In contrast, testosterone did not increase these bone indices in either OVX or ORX rats; rather, it increased bone separations by decreasing bone strength. Testosterone treatment improved trabecular histomorphometry slightly in OVX rats. The results of the present study are concordant with our previous findings that exogenous oestrogen treatment can prevent osteoporosis in either OVX or ORX rats, whereas exogenous testosterone cannot.
Koh
E T
ET
Department of Nutritional Sciences, College of Allied Health, University of Oklahoma, Health Sciences Center, Oklahoma City 73104, USA.
Yeh
J K
JK
Bourdeau
J E
JE
Chen
M M
MM
Om
A S
AS
D045930:Anabolic Agents / Q000494:pharmacology*; D000821:Animal Feed; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000097:blood / Q000652:urine; D000242:Cyclic AMP / Q000652:urine; D003692:Delayed-Action Preparations; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology*; D005260:Female; D005632:Fructose / Q000008:administration & dosage; D008275:Magnesium Deficiency / Q000097:blood / Q000503:physiopathology* / Q000652:urine; D008297:Male; D009919:Orchiectomy; D010024:Osteoporosis / Q000517:prevention & control; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood / Q000652:urine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000031:analogs & derivatives* / Q000494:pharmacology
D045930:Anabolic Agents; D003692:Delayed-Action Preparations; D010281:Parathyroid Hormone; D010758:Phosphorus; D005632:Fructose; D013739:Testosterone; D004958:Estradiol; D000242:Cyclic AMP; C016131:testosterone 17 beta-cypionate; D002118:Calcium